Rózga Karolina, Błauż Andrzej, Moscoh Ayine-Tora Daniel, Puścion Ernest, Hartinger Christian G, Plażuk Damian, Rychlik Błażej
Department of Organic Chemistry, Faculty of Chemistry, University of Lodz, 12 Tamka, 91-403 Łódź, Poland.
Cytometry Lab, Department of Oncobiology and Epigenetics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska, 90-236 Łódź, Poland.
ACS Omega. 2024 Jul 23;9(31):33845-33856. doi: 10.1021/acsomega.4c03602. eCollection 2024 Aug 6.
Synthesis and biological activity of two series of modified side chain methotrexate (MTX) derivatives are presented, one with a ferrocenyl moiety inserted between the pteroyl and glutamate portions of the molecule and the other with glutamate substituted for short chain amino acids. Ferrocenyl derivatives of MTX turned out to be rather moderate inhibitors of dihydrofolate reductase (DHFR) although molecular modeling suggested more effective interactions between these compounds and the target enzyme. More interestingly, ferrocene-decorated MTX derivatives were able to impede the proliferation of four murine and human cell lines as well as their methotrexate-resistant counterparts, overcoming the multidrug resistance (MDR) barrier. They were also able to directly interact with Abcc1, an MDR protein. Of the amino acid pteroyl conjugates, the γ-aminobutyric acid derivative was an efficient inhibitor of DHFR but had no effect on cell proliferation in the concentration range studied while a taurine conjugate was a poor DHFR inhibitor but able to affect cell viability. We postulate that modification of the methotrexate side chain may be an efficient strategy to overcome efflux-dependent methotrexate resistance.
本文介绍了两个系列的修饰侧链甲氨蝶呤(MTX)衍生物的合成及生物活性,其中一个系列是在分子的蝶酰和谷氨酸部分之间插入了二茂铁基团,另一个系列是用谷氨酸取代了短链氨基酸。MTX的二茂铁衍生物结果显示是相当温和的二氢叶酸还原酶(DHFR)抑制剂,尽管分子模拟表明这些化合物与靶酶之间存在更有效的相互作用。更有趣的是,二茂铁修饰的MTX衍生物能够阻碍四种鼠类和人类细胞系及其耐甲氨蝶呤对应物的增殖,克服多药耐药(MDR)障碍。它们还能够直接与一种MDR蛋白Abcc1相互作用。在氨基酸蝶酰共轭物中,γ-氨基丁酸衍生物是DHFR的有效抑制剂,但在所研究的浓度范围内对细胞增殖没有影响,而牛磺酸共轭物是较差的DHFR抑制剂,但能够影响细胞活力。我们推测,甲氨蝶呤侧链的修饰可能是克服外排依赖性甲氨蝶呤耐药性的有效策略。